The global veterinary dermatology drugs market size was valued at USD 10.51 billion in 2025 and is projected to grow from USD 11.51 billion in 2026 to USD 23.83 billion by 2034, registering a CAGR of 9.52% during the forecast period from 2026 to 2034. North America dominated the veterinary dermatology drugs market with a market share of 39.5% in 2025.
Veterinary Dermatology Drugs refers to medications used to diagnose, treat, and manage skin disorders in companion and livestock animals, including bacterial and fungal infections, parasitic infestations, allergic dermatitis, and inflammatory skin conditions. Growth is driven by increasing pet ownership, rising awareness of animal health, expanding veterinary care services, advancements in dermatological therapeutics, and the growing demand for effective treatments that improve animal health and quality of life.
Download a Free Sample To learn more about this report,
Increasing Use of Novel Therapies for Canine Atopic Dermatitis
The veterinary dermatology drugs market is increasingly shifting toward targeted therapies for chronic allergic skin conditions, particularly canine atopic dermatitis. Newer treatments aim to control itching and inflammation through more specific biological or immunological pathways than conventional broad-spectrum therapies. This is supporting a move toward longer-term disease management and treatment approaches tailored to the underlying mechanisms of dermatological disease.
In January 2025, the U.S. Food and Drug Administration approved an expanded indication for a veterinary monoclonal antibody therapy for controlling pruritus associated with allergic dermatitis in dogs, extending the clinical use of targeted dermatology treatment.
Growing Development of Long-Acting Dermatology Treatments
Veterinary dermatology is seeing greater interest in treatments that reduce the frequency of administration and simplify ongoing care. Long-acting injectable therapies can improve treatment convenience for owners while helping veterinarians maintain more consistent disease management in animals with chronic skin conditions. This is creating a shift away from treatment strategies that depend entirely on frequent oral or topical administration.
In March 2025, the European Medicines Agency authorized a veterinary dermatology product with an extended dosing interval for dogs, reflecting continued development of longer-acting approaches for chronic allergic skin disease.
Increasing Prevalence of Companion Animal Skin Disorders
Skin disorders are among the common health conditions affecting dogs and cats, creating sustained demand for veterinary diagnosis and treatment. Allergies, infections, parasitic conditions, and inflammatory diseases can require repeated or long-term pharmaceutical intervention. Growing attention to companion-animal health is consequently increasing the number of animals receiving veterinary dermatology care.
In September 2024, veterinary surveillance data published in the United Kingdom identified skin disorders among the frequently recorded health problems in dogs presented to primary-care veterinary practices, highlighting the continuing clinical burden of dermatological disease.
High Cost of Advanced Veterinary Dermatology Therapies
Novel veterinary dermatology drugs, particularly targeted biologic and specialty therapies, can carry higher treatment costs than conventional medications. Long-term treatment requirements can further increase expenditure for owners managing chronic conditions. Cost sensitivity may therefore lead some owners to select older therapies, reduce treatment frequency, or delay veterinary follow-up.
In February 2025, veterinary clinical guidance continued to emphasize treatment-cost considerations when selecting long-term therapies for chronic canine dermatological conditions, particularly where multiple therapeutic options are available.
Expansion of Veterinary Telemedicine for Chronic Skin Conditions
Digital veterinary consultations can provide an additional channel for monitoring animals with recurring dermatological conditions, particularly when treatment response and visible skin changes can be assessed remotely. Follow-up consultations can support medication management and help identify cases requiring an in-person examination. Wider use of telemedicine therefore creates opportunities for pharmaceutical companies and veterinary practices to support ongoing dermatology treatment programs.
In April 2025, veterinary professional organizations continued expanding guidance for telemedicine and telehealth services, supporting the use of digital tools for selected follow-up and monitoring activities in companion-animal care.
Antimicrobial Resistance Complicates Treatment of Veterinary Skin Infections
Bacterial skin infections can require antimicrobial treatment, but inappropriate or repeated antimicrobial use can contribute to the development of resistant organisms. Resistance can reduce the effectiveness of commonly used veterinary dermatology drugs and increase reliance on diagnostic testing and alternative treatments. Veterinarians must therefore balance effective infection control with antimicrobial stewardship.
In November 2024, international veterinary health authorities continued to emphasize responsible antimicrobial use in animals as part of efforts to limit antimicrobial resistance, reinforcing the need for targeted treatment of bacterial dermatological infections.
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Dominated the Market with 41.6% Share in 2025
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment accounted for the largest share of the global veterinary dermatology drugs market at 41.6% in 2025, driven by their widespread use in managing inflammation, pain, and skin disorders in companion and livestock animals. Their rapid therapeutic action, broad clinical applications, and increasing veterinary prescriptions for allergic and inflammatory skin conditions continue to strengthen the segment’s dominant market position.
Request Customizationto receive a tailored report.
Small Animals are Projected to Register the Fastest Growth at a CAGR of 8.67%
The Small Animals segment is expected to expand at the fastest CAGR of 8.67% during 2026–2034, supported by rising pet ownership, increasing awareness of animal skin health, and growing expenditure on companion animal healthcare. The increasing prevalence of allergic dermatitis, parasitic infections, and fungal skin diseases in dogs and cats, along with greater access to advanced veterinary care, is accelerating demand for dermatology drugs in this segment.
Veterinary Hospitals Dominated the Market with 56.9% Share in 2025
The Veterinary Hospitals segment held the largest market share of 56.9% in 2025, owing to the availability of specialized veterinary professionals, advanced diagnostic capabilities, and comprehensive treatment services for complex dermatological conditions. Rising patient visits for chronic skin disorders, increasing adoption of advanced therapeutics, and expanding investments in veterinary healthcare infrastructure continue to reinforce the segment’s leading position.
Speak to an Analystto discuss market opportunities.
North America dominated the veterinary dermatology drugs market with a 39.5% market share, valued at USD 4.15 billion in 2025. The region is projected to grow at a CAGR of 7.85% during the forecast period. Growth is driven by high pet ownership rates, increasing expenditure on companion animal healthcare, growing prevalence of allergic skin disorders in pets, and strong availability of advanced veterinary dermatology therapies. Continuous innovation in monoclonal antibodies, antipruritic drugs, and veterinary biologics further supports regional market expansion.
The United States accounted for an estimated USD 3.62 billion of the market in 2025, making it the largest contributor in North America. Growth is supported by high spending on pet healthcare, widespread access to specialty veterinary clinics, increasing diagnosis of atopic dermatitis and skin infections, and strong adoption of innovative dermatology treatments.
Canada generated an estimated USD 0.53 billion in 2025. Rising pet adoption, increasing awareness of animal skin health, expanding veterinary services, and growing demand for prescription dermatology medications continue to support market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.4% of the veterinary dermatology drugs market, reaching USD 2.88 billion in 2025. The market is supported by increasing companion animal ownership, strong veterinary healthcare infrastructure, growing awareness of dermatological disorders in animals, and rising demand for advanced topical and systemic therapies. Continuous investments in animal health and veterinary pharmaceuticals contribute to regional expansion.
Germany led the European market with an estimated value of USD 0.71 billion in 2025. The country's well-established veterinary care network, high pet healthcare expenditure, and growing adoption of innovative dermatology drugs continue to drive market growth.
The United Kingdom represented an estimated USD 0.46 billion in 2025. Growth is driven by increasing pet insurance coverage, expanding veterinary specialty practices, and rising awareness regarding early diagnosis and treatment of skin diseases in companion animals.
Asia Pacific accounted for 21.8% of the veterinary dermatology drugs market, valued at USD 2.29 billion in 2025. The region is projected to grow at the fastest CAGR of 9.74% during the forecast period. Growth is fueled by increasing pet ownership, rising disposable income, expanding veterinary healthcare infrastructure, and growing awareness of companion animal wellness. Increasing investments in animal healthcare continue to strengthen regional market growth.
China accounted for an estimated USD 1.05 billion in 2025, making it the largest market in Asia Pacific. Growth is supported by rapid urbanization, increasing pet adoption, expanding veterinary hospitals, and rising demand for advanced dermatological therapies for companion animals.
Japan generated an estimated USD 0.55 billion in 2025. The country's mature pet care industry, advanced veterinary services, growing aging pet population, and increasing demand for premium animal healthcare products continue to support steady market growth.
Latin America accounted for 6.3% of the veterinary dermatology drugs market, reaching USD 0.66 billion in 2025. Increasing pet ownership, expanding veterinary healthcare services, and growing awareness regarding skin disorders in companion animals are supporting regional market growth.
Brazil accounted for an estimated USD 0.29 billion in 2025, making it the largest market in Latin America. Growth is supported by one of the world's largest pet populations, increasing veterinary expenditure, improving access to animal healthcare services, and rising adoption of dermatology treatments.
The Middle East & Africa represented 5.0% of the veterinary dermatology drugs market, totaling USD 0.53 billion in 2025. Increasing investments in veterinary healthcare, rising companion animal adoption, expanding veterinary clinics, and improving awareness of pet skin diseases are supporting regional market expansion.
The United Arab Emirates (UAE) accounted for an estimated USD 0.14 billion in 2025. The country's market is driven by growing pet ownership, increasing expenditure on premium veterinary care, expanding specialty veterinary hospitals, and rising demand for advanced dermatology medications for companion animals.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Veterinary Point of Care Diagnostics Market Size, Share, 2034
Pet Care Market Size, Share, Growth, Analysis, Report, 2034
Farm Animal Healthcare Market Size, Share, Growth, Analysis, 2034
Veterinary Pharmaceutical Drugs Market Size, Share, Growth, 2034
Veterinary Vaccines Market Size, Share, Growth, Analysis, 2034
Veterinary Rehabilitation Services Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com